BS--scores were brought down by in inclusion of moderate patients included in the trial on a 1:1 ratio, who decline at a faster pace over time. Otherwise, data in mild patients out to one year was good enough for FDA approval if the same results hold up in the Phase III trials. In case you haven't noticed, SAVA's market cap exceeds that of AVXL by 47% and the FDA has worked closed with SAVA in establishing SPAs covering its Phase III trials.
News 
Market Data 
Discover 
